- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.06. | Bioz, Inc.: Teknova Expands Digital Publication Experience with Bioz Content Hub Integration | 292 | ACCESS Newswire | PALO ALTO, CA / ACCESS Newswire / June 16, 2026 / Bioz, Inc., an innovative platform focused on extracting and syndicating insights from scientific publications, announced its continued collaboration... ► Artikel lesen | |
| ALPHA TEKNOVA Aktie jetzt für 0€ handeln | |||||
| 01.06. | Alpha Teknova, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.05. | Alpha Teknova, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.05. | Alpha Teknova GAAP EPS of -$0.08 beats by $0.01, revenue of $11.07M beats by $0.85M | 1 | Seeking Alpha | ||
| 07.05. | Alpha Teknova Q1 2026 slides: 13% revenue growth, margins expand | 1 | Investing.com | ||
| 06.05. | Alpha Teknova, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.04. | Alpha Teknova, Inc.: Teknova to Report First Quarter 2026 Financial Results on May 6, 2026 | 1 | GlobeNewswire (USA) | ||
| 19.03. | Alpha Teknova stellt Wachstumsplan vor: EBITDA-Profitabilität bis 2027 angestrebt | 1 | Investing.com Deutsch | ||
| 02.03. | Alpha Teknova, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.02. | Alpha Teknova, Inc. Q4 Loss Decreases | - | RTTNews | ||
| 27.02. | Teknova outlines 20%-25% long-term revenue growth target while investing $2M annually in commercial capabilities | 2 | Seeking Alpha | ||
| 27.02. | Teknova Q4 2025 slides: gross margins surge to 33% on efficiency gains | 1 | Investing.com | ||
| 26.02. | Alpha Teknova GAAP EPS of $0.09 beats by $0.18, revenue of $10M beats by $0.39M | 1 | Seeking Alpha | ||
| 26.02. | Alpha Teknova, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.02. | Alpha Teknova, Inc.: Teknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 | 2 | GlobeNewswire (USA) | ||
| 06.11.25 | Alpha Teknova, Inc.: Teknova Reports Third Quarter 2025 Financial Results | 200 | GlobeNewswire (Europe) | Third quarter 2025 total revenue was $10.5 million, up 9% from prior yearAchieves five consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 2,330 | 0,00 % | PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse des ersten Quartals 2026 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DES ERSTEN QUARTALS 2026
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA BERICHTET ÜBER... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,220 | +5,26 % | Innovation in der Forschung: Chancen bei Vertex Pharmaceuticals, BioNxt Solutions und BioNTech! | In Sozialen Medien findet man allerlei negative Kommentare und Memes zum Pfizer Konzern. Eine sehr populäre Behauptung lautet, dass der von deutschen Einwanderern in New York gegründete Konzern (Karl... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,820 | +1,26 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 4,000 | +2,83 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 70,92 | +1,75 % | Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) | REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the conditionPeople living with FCS have extremely high triglyceride levels and... ► Artikel lesen | |
| ATAIBECKLEY | 4,400 | +9,45 % | AtaiBeckley to join Russell 2000, 3000 indexes | ||
| ALDEYRA | 1,510 | -4,43 % | Aldeyra appoints Darlene Deptula-Hicks to board of directors | ||
| ADAPTIVE BIOTECHNOLOGIES | 18,180 | +2,13 % | Adaptive Biotechnologies Corp - 8-K, Current Report | ||
| ABCELLERA BIOLOGICS | 6,400 | +9,03 % | ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains? | ||
| BIOMERIEUX | 70,75 | +1,51 % | BioMérieux Aktie steigt nach FDA Antrag für Vaginitis Panel | ||
| AC IMMUNE | 2,215 | +3,02 % | AC Immune SA: AC Immune First Quarter 2026 Financial and Corporate Updates | AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers... ► Artikel lesen | |
| 10X GENOMICS | 31,280 | -0,37 % | 10x Genomics, Cleveland Clinic Team Up on Bladder Cancer Diagnostics | ||
| AGIOS | 33,200 | +4,40 % | TD Cowen empfiehlt Biotech-Aktie: Agios überzeugt mit starkem Thalassämie-Geschäft | ||
| BIOXCEL THERAPEUTICS | 1,095 | -0,90 % | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia... ► Artikel lesen | |
| AGENUS | 2,520 | -0,79 % | Agenus Inc.: Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026 | Data reflect an additional year of follow-up from the 123-patient cohort in the Phase 1b study Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three-year... ► Artikel lesen |
Das Unternehmen ALPHA TEKNOVA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,310 (+5,68 %) liegt der Kurs bei 5,770 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALPHA TEKNOVA INC finden Sie auf Wallstreet Online.